9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma, Advanced

Estimated Enrollment: 42

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Progression free survival (PFS) at 12 weeks,  Progression-free survival (PFS),  Objective response (OR), Disease control (DC) at 12 weeks

Interventions: Lurbinectedin,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: April 8, 2019

Completion Date: March 1, 2022

Last  Posted Date: August 5, 2019

Location: A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

Website Link: https://ClinicalTrials.gov/show/NCT03213301

Was this article helpful?
Dislike 0